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Abstract
Background
Leprosy control is based on early diagnosis and multidrug therapy. For treatment purposes,
leprosy patients can be classified as paucibacillary (PB) or multibacillary (MB), according to
the number of skin lesions. Studies regarding a uniform treatment regimen (U-MDT) for all
leprosy patients have been encouraged by the WHO, rendering disease classification
unnecessary.
Methodology and findings
An independent, randomized, controlled clinical trial conducted from 2007 to 2015 in Brazil,
compared main outcomes (frequency of reactions, bacilloscopic index trend, disability pro-
gression and relapse rates) among MB patients treated with a uniform regimen/U-MDT
(dapsone+rifampicin+clofazimine for six months) versus WHO regular-MDT/R-MDT (dap-
sone+rifampicin+clofazimine for 12 months). A total of 613 newly diagnosed, untreated MB
patients with high bacterial load were included. There was no statistically significant differ-
ence in Kaplan-Meyer survival function regarding reaction or disability progression among
patients in the U-MDT and R-MDT groups, with more than 25% disability progression in both
groups. The full mixed effects model adjusted for the bacilloscopic index average trend in
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time showed no statistically significant difference for the regression coefficient in both
groups and for interaction variables that included treatment group.
During active follow up, four patients in U-MDT group relapsed representing a relapse
rate of 2.6 per 1000 patients per year of active follow up (95% CI [081, 62] per 1000). Dur-
ing passive follow up three patients relapsed in U-MDT and one in R-MTD. As this period
corresponds to passive follow up, sensitivity analysis estimated the relapse rate for the
entire follow up period between 29- and 45 per 1000 people per year.
Conclusion
Our results on the first randomized and controlled study on U-MDT together with the results
from three previous studies performed in China, India and Bangladesh, support the hypothe-
sis that UMDT is an acceptable option to be adopted in endemic countries to treat leprosy
patients in the field worldwide.
Trial registration
ClinicalTrials.gov: NCT00669643
Author summary
Since the introduction of multidrug therapy for leprosy in the 80’s, different classification
criteria for leprosy patients have been proposed and treatment has been progressively
shortened. Currently, leprosy patients are classified into paucibacillary/PB and multibacil-
lary/MB based on the number of skins lesions. MB patients (over 5 skin lesions) receive
three drugs (rifampicin, dapsone, clofazimine) for 12 months, while PB patients (up to 5
skin lesions) receive two drugs (rifampicin, dapsone) for 6 months. We conducted a ran-
domized clinical trial to evaluate the efficacy of a uniform treatment (U-MDT) for both
PB and MB leprosy patients, regardless any classification criteria. The current study
includes results from: laboratory tests (bacilloscopic index/BI, serology and histopathol-
ogy), clinical evaluation during a long follow-up, and uses adequate epidemiological anal-
ysis that gives robust evidence on main parameters used to evaluate the efficacy of U-
MDT.
This study reports data among MB leprosy patients treated with regular/R-MDT and
uniform/U-MDT regarding: (i) The frequency of leprosy reactions; (ii) BI decrease, (iii)
Disability progression and (iv) Relapse. Overall, our results showed that there was no sta-
tistically significant difference in these outcomes for both treatment groups. In this sense,
U-MDT can be considered as part of leprosy policy by control programs in endemic
countries.
Introduction
In 1981, the World Health Organization (WHO) recommended the use of multidrug therapy
(MDT) for leprosy. Since then, the disease prevalence dropped, but the case detection rate did
not decrease and currently many countries still present high detection rates [1]. According to
the WHO, in 2014 more than 200.000 new leprosy cases were detected worldwide. Addition-
ally, since the implementation of MDT in early 80’s, the duration of treatment has been halved
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from 24 to 12 months for MB patients and from 12 to 6 months for PB patients. On the other
hand, no new standard treatment scheme for leprosy patients has been proposed. Leprosy
remains a poorly understood infectious disease and in several endemic countries its diagnosis,
treatment and control have been carried out in large scale, yet the effectiveness of these pro-
grams is yet uncertain [2].
Leprosy is caused by Mycobacterium leprae, a highly infectious microorganism with low vir-
ulence, meaning that only a small proportion of those infected will manifest the disease. Lep-
rosy presents a wide spectrum of clinical manifestations, reflecting the interaction of the bacilli
and the immune response of the host. In 1966, Ridley and Jopling proposed a disease classifica-
tion system based on clinical, histological and bacteriological data. This classification includes
two polar forms, tuberculoid (TT) and lepromatous (LL) in which TT patients present with
few bacilli and strong cellular immunity response while LL ones have high bacterial load and
weak cellular immunity. Additionally, three intermediary forms lie between the poles: border-
line-tuberculoid (BT), borderline (BB), and borderline lepromatous (BL) [3]. Later, an early
indeterminate leprosy form (I) was included in this classification system. In 1982, the WHO
recommended two standardized multidrug therapy (MDT) regimens for leprosy, one for I, TT
and BT leprosy cases and the other for BB, BL and LL cases. However since this classification
requires clinical, histological and bacteriological data, it was very difficult for leprosy control
fieldworkers to adopt it. Therefore, the classification system for treatment purposes has been
later simplified to two leprosy types: paucibacillary leprosy (PB) referring to patients with a
low bacillary load, and multibacillary (MB) patients with high bacillary load, based on results
from bacilloscopy of Ziehl–Neelsen stained skin smears. The WHO classification into MB or
PB patients for treatment purposes proposed in 1997 is based on the number of skin lesions as
a proxy for the bacteriological data and defines two different treatment regimens: MB patients
(over 5 skin lesions) receive twelve months of daily dapsone plus clofazimine and monthly
rifampicin doses while for PB patients (up to 5 skin lesions), treatment consists of six months
of daily dapsone plus monthly rifampicin doses. The rationale for these two regimens is that
the probability of the presence of a naturally resistant bacillus, among those infecting a patient,
is proportional to the bacillary load. Also, in order to avoid the selection of drug resistant
bacilli, patients with high bacillary load need to be treated longer and with one additional drug
[4]. On the other hand, to avoid side effects, patients with low bacillary load should not be over
treated.
The duration of treatment for leprosy and tuberculosis has always been a controversial
issue due to the presence of persistent bacilli. In leprosy, the permanence of bacilli, despite
months or years of chemotherapy is probably due to the fact that M. leprae has low multi-
plication rate, i.e., low metabolism, making this pathogen less susceptible to destruction by
chemotherapy.
Leprosy control programs are based on early diagnosis and treatment of cases, i.e., elimina-
tion of infectious sources and the relapse rate is considered the main treatment outcome. In
this context, the operational WHO classification system based on the number of skin lesions
can lead to misclassifications of MB as PB cases, consequently increasing the chances of re-
lapses. During the chronic course of leprosy, new neurological damage leading to further phys-
ical disability can occur. In the perspective of the patient and also of the medical care staff,
disability is an important clinical outcome that has never been included in leprosy chemother-
apy trials [5].
The uniform treatment for leprosy (U-MDT) consists of daily intake of dapsone plus clofa-
zimine and monthly rifampicin for six months, despite any type of patient’s classification.
Therefore, the adoption of a uniform treatment for all cases would render disease classification
unnecessary, simplifying the implementation of leprosy treatment at primary care. The need
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for evaluating a uniform treatment for leprosy patients was included in the WHO Technical
Advisory Group report in 2002, and in 2003 a WHO U-MDT trial without a control group
was launched in India and China [6].
This original report describes for the first time, long-term results of the four main outcomes
of MB patients that participated in the open label randomized Clinical Trial of Uniform Multi-
drug Therapy conducted in Brazil (U-MDT/CT-BR), concerning: (i) frequency of reactions;
(ii) trends of bacteriological index (BI) during treatment and follow up; (iii) disability progres-
sion; and (iv) relapse rates [7] and [8].
Methods
Ethics considerations
This study was performed under the international (Helsinki) and Brazilian research regula-
tions and was approved by the National Ethics Commission of Research (CONEP) of the Min-
istry of Health, protocol number 12949/2007. Written informed consent was required from all
the patients prior to their inclusion in the study. For patients aged six to 17 years, written
parental consent was mandatory. Data confidentiality was strictly guaranteed. Patients were
free to leave the study, if they desired, and opt for the R-MDT regimen outside the study.
Study design
An open label randomized clinical trial was conducted, from March 2007 to January of 2015,
at two Brazilian leprosy reference centres (Fundac¸ão Alfredo da Matta (FUAM) in Manaus,
Amazonas State, north region and Centro de Dermatologia Dona Libaˆnia (CDERM) in Forta-
leza, Ceara´ State, northeast region). ClinicalTrials.gov registered its protocol under the identi-
fier–NCT 00669643. In this trial, all patients coming to these dermatology clinics, which are in
charge of treating skin diseases in general, were examined. In this report, the study population
included newly diagnosed, previously untreated PB and MB leprosy patients and returning
defaulters and relapse cases, provided that the last treatment dose was taken more than five
years prior to the enrollment in the study. All of the leprosy patients were between six- 65
years old. Patients were excluded if they were receiving tuberculosis/TB or steroid treatment,
had overt signs of acquired immune deficiency syndrome, they did not reside permanently in
the area or were unable to visit the clinic every month during the treatment and follow-up
periods. Patients were classified as MB according to the criteria proposed by the WHO, i.e.,
patients with more than five skin lesions. Until 2011, the study included 613 newly diagnosed
MB leprosy patients with high bacterial load and among them, 323 were randomized into the
U-MDT group and 290 into the WHO regular regimen (R-MDT) group.
Sample size
In order to ensure a precise estimate of relapses among MB patients, a sample size of at least
278 MB patients in each study arm was calculated. This value is based on an alfa error of 005 a
betta error of 020, i.e., a power of 80%, a ten years relapse risk for the U-MDT group of nine
per cent, and a relapse risk of 003 in the R-MDT group for the same period.
Randomization
Before starting the randomization and the controlled clinical trial, all study protocols (standard
operational procedures/SOP) and clinical report forms (CRF) were evaluated in an open and
uncontrolled cohort pilot study with 78 patients, conducted from 2004–2006 at the Federal
University of Minas Gerais, Brazil.
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Randomization was performed in order to evaluate whether there were differences in the
two treatment modalities. All patients who met the inclusion criteria, independent of MB or
PB status were randomized into the experimental (U-MDT) or the control (R-MDT) group.
Prompt action was essential because the experimental treatment group for PB patients began
treatment with three drugs while the control group was treated with two drugs. Since for MB
patients the drug regimen was the same for U-MDT and R-MDT, differing only in its dura-
tion, MB patients were randomized after six months of initiating therapy when the U-MDT
group discontinued treatment, while the control R-MDT group continued treatment for addi-
tional six months.
Procedures
A randomization table was created with codes for all patients in the study, based on a random
list of numbers, using the study entrance sequence according to the CRF number. For this
process, the space in the worksheet that contained the randomization code was covered with
the same material used in lottery scratch cards, so that the printed numbers were not visible.
This code determined the directions for treatment group of each patient as follows: when the
code corresponded to an odd number, the patient was part of the experimental group 1 or 3
(U-MDT), according to their classification as PB or MB, respectively. When the code corre-
sponded to an even number, the patient was part of control group 2 or 4 (R-MDT), according
to the classification as PB or MB, respectively. A spreadsheet containing the codes was sent to
the local coordinator of each recruiting centre, which was responsible for the allocation of the
patients into the study groups. For PB patients, the randomization results were identified
immediately after the inclusion of the patient into the study.
The randomization code of each MB case was kept blind in the spreadsheet until the patient
completed six doses of the MDT regimen, when the local coordinator disclosed the code. Dur-
ing this trial, the local research coordinators were responsible for managing data collection
according to the eligibility criteria and for ensuring the six doses of MDT, keeping the patient
randomization spread sheet under his/her responsibility and coordinating treatment for each
patient. In each centre, the data manager was responsible for coordinating the preparation of
the spreadsheet with the randomization codes and for maintaining a confidential copy of the
spreadsheet containing the randomization results.
At the first visit, the dermatologist in charge performed a complete clinical examination
that included registering the number of skin lesions and affected nerves and collecting skin
biopsies for histopathological examination. Health workers collected blood for liver and renal
function tests, complete blood count, anti-PGL-I ML Flow test and skin smear material from
six sites, including ear lobes and elbows, for bacilloscopy. In each centre, a technician with
extensive experience, examined the Ziehl-Nielsen stained skin smears and generated a bacillo-
scopic index (BI) that ranged from zero to six crosses for each skin site and results were sum-
marized as the average of all six BI (aBI).
During the first year of follow up, patients had a monthly appointment and thereafter,
yearly. The visits included dermato-neurologic examination, blood collection to evaluate liver
function and whole blood counts. Skin smears were collected at the beginning and at the end
of treatment and thereafter yearly. Physicians advised all patients to come to an urgent ap-
pointment in case any sign or symptom of leprosy reaction occurred. Treatment for reaction
was established by the assistant dermatologist and registered in the CRF, and followed the
guidelines established by the Brazilian leprosy control program from the Ministry of Health.
Recurrent leprosy was defined as the reappearance of signs and symptoms of the disease
after completion of MDT, not associated with leprosy reactions, and with an increase in the
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bacillary index (BI) compared to the BI after treatment completion. Patients with suspicion of
relapse were clinically reviewed by the research PI (GOP), by the assistant dermatologist and
by Dr. Sinesio Talhari, an expert member of the independent steering committee, when skin
smears and biopsies were collected.
Disability grade of each patient was the highest grade reported in either eye, foot and hand
as recommended by the WHO. Neurological examination indicating disability in one of these
sites that was previously unaffected was considered as disability progression (DP) and was
used to compare neurological damage in the two study groups. The protocol, the study design,
preliminary results of this trial, and the patients’ profile and satisfactions have been published
[7,9,10].
Statistical analyses
We used Student t test for continuous variables and Chi-square for dichotomous ones to com-
pare the distribution of the baseline characteristics in each study arm. We evaluated the first
reaction since the beginning of treatment using a Kaplan-Meyer survival function for the
experimental and the control groups and a log-rank test. The survival analysis included the
first six months of treatment. To compare the number of reaction episodes between the two
groups after 180 days of treatment, we fitted a Zero-inflated negative binomial regression
model to the number of reaction as the dependent variable and the treatment group as the
independent variable with the log of follow up days of each patient as an offset variable.
In order to evaluate the BI trend over time after 180 days from the onset of treatment, we
fixed a multilevel linear model with mixed effects, i.e., a random intercept model. The aBI
(average BI) was the independent variable and the dependent variables were time (in days),
initial aBI categorized as high (aBI4) and low (aBI<4), study arm (U-MDT and control), and
three interaction variables combining the previous ones, two by two. For this analysis, time
zero was the first day of the seventh month after the beginning of treatment, i.e., the randomi-
zation moment for MB patients. For clarity, the categorized aBI is referred as BI level, in con-
trast with aBI referring to continuous measure, the average of all sites of smear collection. We
evaluated the first disability progression since the beginning of treatment using a Kaplan-
Meyer survival function for experimental and control groups and a log-rank test. These sur-
vival analyses included the first six months of treatment. We estimated the difference of sur-
vival proportion in fixed points of time according to Kaplan Meyer curve and its confidence
interval.
Results
Among the 3217 new cases registered for leprosy treatment at the two reference centers during
the specified 4-year period, 859 (156 PB and 703 MB) agreed to participate in the trial. After
deducting 90 (12.8%) MB patients for irregularity, 613 MB subjects were randomized to the
treatment groups (323 to U-MDT and 290 to R-MDT). From these, 439 (71,7%) complied to
the five years follow up period (239 in U-MDT and 200 in R-MDT). Fig 1 shows the partici-
pants’ flow diagram.
In our study population, the total person-time of follow up was 383391 person-years,
156811 in the U-MDT group and 22658 in the R-MDT group. The median follow up time
was 487 years for both groups, 486 years for U-MDT treatment group and 477 for R-MDT,
meaning that half of the participants were followed for more than 4 years and 10 months.
The baseline characteristics of the two groups (Table 1) show a small unbalance between
the intervention and the control group in relation to the aBI, but the two groups are compara-
ble in all other variables.
Results of U-MDT leprosy clinical trial—Brazil (U-MDT/CT-BR)
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(i) Frequency of leprosy reactions among MB patients
Figs 2 and 3 show the Kaplan-Meyer function of the survival without reaction in both treat-
ment arms and also stratified by BI level. The logrank test for the survival curves showed no
statistically significant difference between groups. By the 180th day (six months) of treatment,
64.14% of participants in U-MDT and 62.23% in R-MDT group were reaction-free indicating
a risk ratio for at least one reaction at the period of 105, CI95% [08554–12968]. Regarding the
number of leprosy reactions developed in each treatment group, the negative binomial model
fitted to the data showed no statistically significant difference compared with the intercept
only model (log likelihood ratio (LLR) test = 29730, df = 2, p = 07681). These results indicate
Fig 1. MB Patients’ selection flow diagram.
https://doi.org/10.1371/journal.pntd.0005725.g001
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lack of association between the number of reactions and the treatment group (p value for the
coefficient = 0,221), meaning that the treatment group did not affect the number of reactions.
When patients were stratified into the aBI as or < 4, no statistically significant difference in
the development of leprosy reactions was seen between the study U-MDT and control R-MDT
groups.
(ii) BI decrease
Fig 4 shows the aBI as a function of time for each MB patient, and Fig 5 shows the linear
adjusted aBI as a function of time. These two figures illustrate the need for a multilevel model
for analysis, as a patient aBI at a fixed time is dependent on the previous aBI measure. This
analysis approach considers the BI time trend of each patient instead of the BI average of all
patients in each time point representing treatment duration.
The full mixed effects model adjusted for the aBI trend—independent variables: treatment
group, aBI level and time, plus three interaction variables—initial aBI and group; time and
group; initial aBI and time—showed no statistical significance for the regression coefficient of
bacilloscopic index of treatment groups and for interaction variables that included treatment
group (‘group X time’ and ‘group X initial aBI’). The full model allowed for treatment effect on
Table 1. Main baseline characteristics of multibacillary leprosy patients stratified according to U-MDT and R-MDT Groups.
CHARACTERISTIC U-MDT
(n = 323)
R-MDT
(n = 290)
MEAN AGE (years) a
AGE GROUPS (years) b
39.63 40.76
0–9 5 1.55% 6 2.07%
10–19 24 7.43% 26 8.97%
40–49 68 21.05% 68 23.45%
30–39 59 18.27% 51 17.59%
20–29 61 18.89% 51 17.59%
50–59 72 22.29% 65 2241%
= > 60 34 10.53% 23 793%
GENDER b
MALE 217 67.18% 193 66.55%
FEMALE 106 32.82% 97 33.45%
BIb (mean) 249 246
BI GROUP
BI<4 169 5232% 145 5000%
BI> = 4 154 47.68% 145 50.00%
Ridley Jopling Classificationb
I 3 0.93% 2 0.69%
LL 71 21.98% 59 20.42%
BT 93 28.79% 77 26.64%
BB 71 21.98% 71 24.22%
BL 85 26.32% 81 28.03%
U-MDT: uniform 6 months MDT regimen; R-DMT: regular 12 months MDT; BI: bacilloscopic index; I: indeterminate leprosy; LL: lepromatous leprosy; BT:
borderline tuberculoid leprosy; BB: borderline borderline leprosy; BL: borderline lepromatous leprosy
a t test, p >005
b χ2 test, p>005.
https://doi.org/10.1371/journal.pntd.0005725.t001
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aBI value, on time trend of aBI value and on different effect according to initial aBI. The final
model retained the possible effect of treatment (group variable) on aBI value, of initial aBI
effect on aBI value and of initial aBI effect (interaction of initial aBI and time variable) on time
trend of aBI.
Table 2 shows the final model excluding these two not statistically significant interaction
variables. The log likelihood ratio test comparing the two models showed no statistically signif-
icant difference in BI decrease. Fig 6 shows the daily BI decrease in MB patients in U-MDT
and R-MDT after 180 days of starting treatment and the BI level, with its 95% confidence
interval. No statistically significant difference was observed in the BI decrease of MB leprosy
patients from the U-MDT and R-MDT groups.
(iii) Disability progression
Figs 7 and 8 show the cumulative probability survival without disability progression as a func-
tion of time of follow up. The logrank test for the survival curves showed no statistically signifi-
cant difference between the two treatment groups. At the fifth year after the beginning of the
Fig 2. Kaplan Meyer survival curve of reaction free multibacillary leprosy patients comparing U-MDT versus R-MDT groups.
https://doi.org/10.1371/journal.pntd.0005725.g002
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treatment (1825 days), 33.8% of U-MDT patients had disability progression compared with
30.06% of patients in the R-MDT group, 3.74% difference, 95% CI [- 3.2%, 12.08%]. For those
with aBI < 4, the difference was 2.85% and 95% CI [-6.11%, 11.81%] and for those with
aBI 4 the difference was 4.68% and 95% CI [-2.11%, 11.48%]. No subgroup presented less
than 25% disability progression. These results show no statistically significant difference in dis-
ability progression of MB leprosy patients treated with U-MDT or R-MDT regimens.
(iv) Relapse
Four patients in the U-MDT group relapsed representing a relapse rate of 26 per 1000 patients
per year of follow up (95% CI [081, 62] per 1000) during the active follow up period, which
ended on April 30th, 2015. In the R-MDT group, supposing the same relapse rate, the expected
number of relapses would be five, but no relapse was observed.
During passive follow up (May 1st, 2015-June 1st 2016) three MB patients in U-MDT and
one in R-MDT group relapsed. It was difficult to define accurately the denominator to estimate
Fig 3. Kaplan Meyer survival curve of reaction free multibacillary leprosy patients: Comparing U-MDT versus R-MDT groups by the average
bacilloscopic index/ aBI level.
https://doi.org/10.1371/journal.pntd.0005725.g003
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the relapse rate when passive follow up time was considered. In order to overcome this, we did
a sensitivity analysis, i.e., we estimated the rate using the follow up person-years that results in
an overestimation bias. The estimated rate of relapse for U-MDT group was 4.46 per 1000 peo-
ple per year and for R-MDT 0.44 per 1000 people per year. This means that in the U-MDT
group the overestimated relapse risk in ten years is 4.4%. As the relapse risk is surely lower
than 4.4% in ten years, we consider the U-MDT relapse rate acceptable for use. Thus far, the
recruitment centres participating in the U-MDT trial continue to follow up of patients.
Table 3 describes sociodemographic and clinical characteristics of the four MB patients
from the U-MDT regimen who relapsed during active follow up. All of these patients had ini-
tial aBI 35 and were classified, according to Ridley Jopling, as lepromatous or borderline
lepromatous leprosy.
Fig 4. Observed average bacilloscopic index/aBI by time (days) for each multibacillary leprosy patient.
https://doi.org/10.1371/journal.pntd.0005725.g004
Fig 5. Adjusted average bacilloscopic index/aBI by time (days) for each multibacillary leprosy patient. *linear adjusted declining trend usually
produces negative values as in this graph, although this is not biological plausible.
https://doi.org/10.1371/journal.pntd.0005725.g005
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Discussion
In this randomized, controlled clinical trial, expert dermatologists with vast experience in lep-
rosy, robust methodology, well-established follow up and high-level epidemiological analysis
Table 2. Analysis of bacilloscopic index decrease among multibacillary patients and parameters of the multilevel linear model with mixed effects.
aBIt Coefficient Standard Error z value p value 95% Confidence
Interval
Treatment group 00910 0810 011 0911 -1496 1677
Ln (Days of follow up) -0005 000056 -956 0000 -00064 -00042
Initial BI 26290 1044 2518 0000 24244 28337
Days X initial BI -0010 00008 -1270 0000 -0012 -00087
BI: bacilloscopic index; Random—effects Parameters: sd (constant) = 07567185 CI95%[06922–08272504]
sd (residual) = 078295 CI95%[0746861–0820779]
https://doi.org/10.1371/journal.pntd.0005725.t002
Fig 6. Daily bacilloscopic index decrease in multibacillary leprosy patients allocated into the U-MDT and the R-MDT groups after 180th days of
starting treatment.
https://doi.org/10.1371/journal.pntd.0005725.g006
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were employed to compare the main outcomes observed between regular MDT and uniform
MDT regimens. This comparison included the relapse rate, the frequency of leprosy reactions,
the bacteriological index trends during treatment and follow up and disability progression.
The risk of relapse is considered the main outcome measure in a clinical trial and in leprosy,
the reduction of treatment duration may raise the possibility of insufficient treatment that
would result in very early relapses, similarly to what has been shown in four months tuberculo-
sis treatment [11]. Our study found a higher rate of relapses in the U-MDT group, but without
statistically significant difference compared with R-MDT. This rate is acceptable for leprosy
control programs because the superior limit of the confidence interval is lower than 1%. How-
ever, we point out that the lack of an accurate, simple and standardized criterion for the diagno-
sis of relapse, limits any further comparison of results reported by different studies. Therefore,
we consider that a precise estimate of the relapse rate after MDT is unlikely to be obtained,
because relapses are rare events that may take place long after treatment conclusion. Addition-
ally, accurate estimates of leprosy relapse require both large group of patients and long follow
up after treatment. In this regard, considering the long evolution of leprosy, one potential draw-
back of our study may be the relatively short follow up, which does not allow the detection of
late relapses cases. However, previous studies have reported a higher rate of early relapses com-
pared to late events. A study with proper sample size showed that the risk of early relapses,
defined as the ones observed before 5 years after treatment conclusion is higher than late relapse
risk. Also, more than half of the total relapses were observed in the early period [12].
Fig 7. Cumulative proportion of MB leprosy patients without Disability Progression (Kaplan Meier curve).
https://doi.org/10.1371/journal.pntd.0005725.g007
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One international open trial on U-MDT performed in India and published in 2008 [13]
reported six relapses and all of them were considered early relapses. Three of them were
observed at the first year, two at the second and one at the third year of monitoring. In this
study, early relapses were diagnosed based only on clinical examination by primary care
Fig 8. Cumulative proportion without Disability Progression of MB leprosy patients (Kaplan Meier curve).
https://doi.org/10.1371/journal.pntd.0005725.g008
Table 3. Socio-demographic and clinical characteristics of MB patients from the U-MDT arm that relapsed during active follow up period.
Case
#
Age at diagnosis
(years)
Gender Date of
U-MDT start
(month/ year)
Ridley
Jopling Classification
at diagnosis
Relapse
Date
(month/
year)
Ridley
Jopling Classification
at relapse
Initial
aBI
Lowest aBI/
date
(month/
year)
aBI
at
Relapse
CE
0126
32 M 06/2007 BL 09/2011 LL 4.0 1.25
06/2010
4.0
CE
0188
20 M 09/2007 LL 11/2014 LL 3.5 3.0
07/2014
4.2
CE
0208
17 M 10/2007 LL 04/2015 LL 4.75 1.0
09/2011
4.0
AM
0014
33 M 04/2007 LL 04/2011 LL 4.5 0.25
07/2010
3.0
M: male aBI: average bacilloscopic index; BL:borderline lepromatous; LL: lepromatous.
https://doi.org/10.1371/journal.pntd.0005725.t003
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workers. The Chinese trial on U-MDT, published in 2015 that defined relapses based on skin
smear results, reported one relapse observed at 13 months of follow up, among 144 leprosy
patients monitored for up to six years [14]. In our open cohort pilot study for CRF test, among
the 19 MB patients included, two relapsed ten years after ending U-MDT. Both patients were
classified as LL, and upon starting U-MDT they presented BI = 2.75 and BI = 5.0 and at the
time of relapse they had BI = 5.0 and BI = 3.75 respectively. These two relapse cases were not
included in the statistical analysis of U-MDT/CT-BR. A recent publication from Bangladesh
compared outcomes of two similar open cohorts, U-MDT-MB and R-MDT-MB and suggested
that shortening the duration of treatment from 12 to six months did not increase relapse rates
[15]. Therefore considering evidences of the significant occurrence of early versus late relapses,
we can consider that our follow up was enough to detect early relapses, which according to
published studies, may represent the majority of these events.
In the current study our definition of leprosy relapse was based on clinical, histopatholog-
ical and bacterial data. Additionally, whole genome sequence analysis of M. leprae obtained
from the initial and the relapse skin lesions did not show any association of relapse with drug
resistance mutations and demonstrated that reinfection with a different M. leprae strain can
occur in susceptible MB patients that remain in endemic area after the conclusion of MDT
(Stefani et al, 2017 in press). The results from this recent study suggest that susceptible patients
may be reinfected with a different strain of M. leprae, regardless of the duration of MDT for six
or 12 months and the possibility of reinfection after treatment. It is recognized that the integra-
tion of leprosy control activities in general health care is challenging [16] but our results sup-
port that U-MDT may be used for leprosy control, as the control activities aim the elimination
of infectious sources. Also, the acceptable relapse rate observed in the U-MDT can underscore
the implementation of this simpler treatment regimen in the primary care and this measure
may contribute to avoid potential relapses due to misclassification of patients.
Leprosy reactions need to be monitored since they are the main cause of permanent inca-
pacities and handicaps. The development of leprosy reactions after MDT is often defined by
patients as disease symptoms, interfering in their quality of life. The current study shows that
the incidence of recurrent reactions was not associated with treatment duration. Our results
indicated that the development of leprosy reactions and BI decrease were similar between the
U-MDT and R-MDT groups. An observational study that compared the rate of reactions of
MB patients treated for one or two years showed association between reaction frequency and
treatment duration and with BI [17]. The frequency of leprosy reaction reported previously
was lower than that reported by us, but their analysis considered the initial time of monitoring
as the end of treatment and not the beginning of the treatment as in our study.
The predefined, regular follow up intervals adopted in our study may eventually have
increased the probability of diagnosis of leprosy reaction, especially when compared to the
monitoring in the field by primary care workers reported in India[13]. Also, we acknowledge
that the loss to follow up of patients can represent a limitation in our study due to the long-
term monitoring required in leprosy studies. However, despite patients’ loss, our study
follow up still included enough patients that allowed robust analyses. In addition, we cannot
exclude the possibility of an over surveillance of U-MDT group compared to R-MDT during
monitoring.
The development of disabilities after MDT is also a serious medical event and there is no
gold standard for the evaluation of disability progression after leprosy diagnosis. The U-MDT
group presented higher disability progression; nevertheless this difference was not statistically
significant. It is worth mentioning that the disability progression was high in all treatment
groups and subgroups. The definition of disability progression/DP used in our study although
very specific, has low sensitivity as it is based on the appearance of neurological damage in a
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previously normal limb or eye, but it is unable to detect damage of a previously normal nerve
in the same limb. Our results showed that around 30% of the MB patients had DP after the
beginning of treatment. In terms of disability progression, we found a small difference in the
proportion affected, lower than 4%. However, our trial results highlight the extremely large
proportion of patients that developed new disabilities under both R-MDT and U-MDT. We
recognize that a proportion of neurologic damage progression after diagnosis higher than 30%
can be clearly considered a poor clinical outcome. In this sense, we strongly recommend a con-
sensus definition and criteria to estimate disability progression in leprosy. We also emphasize
the need to include the evaluation of disability progression as part of evaluation of ongoing or
new leprosy treatment.
A prior study on disability progression employing the increase of WHO disability grade or
the Bechelli´s index showed a disability progression incidence rate of 6.5 per 100 person-years
[18], indicating a risk of 27.75% in five years, a value close to our findings. Our results on dis-
ability progression provide evidences that the WHO target to reduce grade 2 disability at diag-
nosis is not a reliable measure of the total disability produced by the disease, as a significant
percentage of MB patient will progress with further neurological lesions, regardless of the
treatment duration of six or 12 months. The disability progression rate represents a main
knowledge gap in leprosy management, i.e., prevention and effective treatment of reactions,
with effective prevention of further neurological damage after diagnosis. Clinical trials, includ-
ing those with a Bayesian design [19], should address the main triggers of disability progres-
sion rate.
Kumar et al. [20] showed the cumulative risk of disability after 4 years of follow-up, estimat-
ing that only 10% of patients were free from disability at the end of this period. This study did
not find statistically significant differences in disability progression between those who com-
pleted 1 year of treatment and defaulters with less than six months of treatment. As their
results come from an observational study, the comparison of groups may have been biased,
because patients with a better clinical response to the initial doses/months of treatment could
have had a higher probability of non-compliance to the full treatment.
Our study employed multilevel analysis of BI decline which considered for each patient, the
initial BI as the control BI, and estimated the mean of BI decrease as a function of time instead
of the decrease of the mean BI for all patients, as used when a traditional linear regression of
BI values against time is estimated. It is worth pointing out that these two approaches estimate
different values for the decrease in time with the traditional regression overestimating it. Al-
though the decline is greater for those taking R-MDT, compared to U-MDT users, these differ-
ences were not statistically significant in this model especially when BI decrease in U-MDT
and R-MDT after 180 days of starting treatment was analyzed, considering the 95% confidence
interval.
The U-MDT/CT-BR trial followed a robust scientific basis [21] therefore the lack of statisti-
cally significant differences in the main clinical outcomes of MB patients treated with U-MDT
or R-MDT including the relapse rate, the frequency of reactions, the bacteriological index
trend and the disability progression, support the adoption of U-MDT as part of a control pol-
icy for leprosy [22]. The U-MDT can potentially simplify the expansion of treatment coverage
to all health entities and reduce the overall rate of relapses and it may also contribute to prevent
under treatment of MB patients misclassified as PB. Additionally the adoption of U-MDT can
help prevent the over treatment of PB patients misclassified as MB, receiving dapsone daily for
six further months. Finally, we acknowledge the need of further clinical trials including the
prevention and treatment of leprosy reactions, and the prevention of new neurological damage
after MDT initiation.
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Conclusion
Our results on the first randomized and controlled study on U-MDT, together with the results
from three previous studies performed in China, India and Bangladesh, support the premise
that U-MDT is an acceptable option to be adopted by leprosy endemic countries, in the field
worldwide.
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